Translational research: The model matters by Deutschman, C. S.
Journal Articles Donald and Barbara Zucker School of MedicineAcademic Works
2018
Translational research: The model matters
C. S. Deutschman
Zucker School of Medicine at Hofstra/Northwell
Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles
Part of the Pediatrics Commons
This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for
inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works. For more
information, please contact academicworks@hofstra.edu.
Recommended Citation
Deutschman CS. Translational research: The model matters. . 2018 Jan 01; 46(5):Article 4753 [ p.]. Available from:
https://academicworks.medicine.hofstra.edu/articles/4753. Free full text article.
Translational Research: The Model Matters
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the Feinstein Institute for Medical Research, Room 3140, 350 Community Drive, Manhasset, NY 
11030
Because critical care research is so diverse and complex, the readers of Critical Care 
Medicine often find it difficult to fully understand, internalize and apply to practice the 
material presented each month. Therefore, authors submitting to the journal are encouraged 
to present their findings in a way that is clinically “accessible”, that is, in a manner that 
maximizes the ability of each individual reader to apply the material to their daily practice. 
This emphasis on clinical context is perhaps most daunting for those engaged in 
“translational research”, where bedside observations need to be reproduced in a model (most 
often an animal) in hopes of identifying some aspect of the underlying biology/pathobiology 
that can lead to novel therapeutic approaches to “translate” back to critically ill patients. The 
failed attempts to identify specific therapies for sepsis over several decades bear witness to 
the difficulty of this approach (1). Perhaps these failures reflect an incomplete assessment of 
the pathobiologic processes that lead to sepsis (2). But recent work also highlights the 
importance of the model (3,4). It is essential that the chosen model mimic the human 
condition of interest, the standard approaches to the management of that condition and the 
outcome criteria used to assess efficacy as closely as possible. That is, the model matters.
The paper by Lewis et al in this edition of the journal presents a case in point (5). In a 
previous publication the authors demonstrated that an early 10% change in core temperature 
(T) and heart rate (HR) following cecal ligation and puncture (CLP, a mouse model of 
sepsis) was associated with a significant risk of death within 7 days (6). The T and HR 
alterations were associated with changes - increases in cytokines and cystatin-C (indicative 
of renal dysfunction), decreases pH/base excess – consistent with a pathobiological state that 
might well underlie the high risk of death. In the current study, the authors used a similar 
approach to examine the effects of antibiotics and/or fluid resuscitation administered either 
at the time when animals met T/HR criteria or after a delay of 2–4 hours, bookending the 
Surviving Sepsis Campaign (SSC) guideline recommendation of 3 hours (7). Thus, the 
experiments were designed as a randomized trial where entry criteria mimicked the situation 
faced by most clinicians, who must initiate interventions based on patients’ clinical findings. 
The study demonstrated that mortality was similar if fluid was given at the time when T/HR 
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criteria were met or when resuscitation was delayed. However, similar delays in the 
administration of antibiotics were associated with a significant increase in mortality. When a 
combination of fluids and antibiotics was investigated, a delay of 4 hours, but not 2 hours, 
reduced survival. These findings are consistent with a recent analysis of data from nearly 
50,000 patients entered into the New York State Department of Health Sepsis database (8).
The study by Lewis et al represents a potentially paradigm-shifting advance in the 
development of a model system to study human sepsis, one in which therapy is initiated 
based on the sorts of clinical data that confront clinicians. The authors also deserve 
commendation for identifying changes in easily measured clinical variables that strongly 
correlate with an adverse outcome, mimicking the approach used by the Sepsis-3 task force 
in developing the new clinical criteria for sepsis/septic shock (9–11) and for using these 
variables to identify an associated CLP-induced state that may identify the pathobiological 
changes underlying adverse outcomes. Indeed, this study sets a standard that others in the 
field should seek to replicate.
But – there’s always a “but”. In formulating their experimental paradigm, Lewis et al chose 
to duplicate the SSC guidelines for resuscitation. Initiating treatment when clinical 
indicators strongly suggest sepsis, as recommended, is appropriate. However, the actual 
treatment provided to the mice in the trial may not be. As per SSC guidelines, resuscitation 
was initiated with a fluid bolus of 30ml/kg (7). This dose may be a good starting point for 
patients with presumed sepsis, but it is insufficient for a mouse subjected to CLP. Most CLP 
investigators provide a minimum initial bolus of 40ml/kg, a substantially greater volume; 
some (myself included) believe that more is required (12). Failure to provide this amount 
leads to death from hypovolemia, not sepsis, a concern reinforced by the 100% mortality in 
the mice studied by Lewis et al. Further, the SSC guidelines recommend that fluid 
resuscitation be continued after the initial bolus, until the resuscitation is “adequate”. 
Providing an animal subjected to CLP with a single bolus of an insufficient amount of fluid 
cannot be construed as “adequate”. Indeed, Lewis et al might have followed the SSC 
paradigm and provided additional fluid based on clinical criteria, avoiding the risk of 
hypovolemia and more completely replicating the clinical situation. Similarly, a single dose 
of antibiotics is not sufficient for either septic patients or mice undergoing CLP, although the 
optimal length of treatment is unknown and may differ in patients and mice. Lewis et al 
replaced “time” with “pathobiological state” to improve concordance between a clinical 
disorder, sepsis, and the animal model used to study that disorder, CLP. Unfortunately, they 
did not seek similar equivalencies in the chosen interventions. Basically, treatment across 
species needs to be equivalent, not identical.
Finally, the 100% mortality of the mice in this study is also problematic. Philosophically, 
one could argue that delaying death by a day or two is not a desirable outcome. More 
importantly, mortality this high is unusual for CLP; with use of fluids and antibiotics, about 
40% of mice survive (12). And this mortality most assuredly is not consistent with clinical 
sepsis; even recent reports on septic shock indicate about 50% survival (10); for sepsis, data 
indicate mortality of about 20% (13).
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In summary, improving the model to more closely mimic the clinical situation is 
tremendously important. As such, the report by Lewis et al, and the fact that their findings 
replicate recent clinical data, may make their approach the new standard. But the study also 
highlights that application of guidelines designed for humans may not be appropriate when 
using an animal model such as CLP. The model matters; but so does pathobiological 
equivalence.
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